A New Combination Proves Itself in Treatment for Type 2 Diabetes

Poll

Question 2. The rationale for combination therapy with SGLT2 inhibitor and a DPP-4 inhibitor is based on:

A. Increased bioavailability of both drugs when administered together.
B. Less glucose production in the presence of a DPP-4 inhibitor in response to the glucosuria produced by SGLT2 inhibition
C. Increased affinity of the SGLT2 inhibitor to its target in the renal tubule in the presence of a DPP-4 inhibitor.
D. None of the above
Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
Related Content
Anjali Dixit, MD, MPH | Credit: Stanford Medicine

GLP-1 Receptor Agonists Not Linked to Post-Op Respiratory Complications

April 25th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations

April 19th 2024
Podcast
Carolyn J. Crandall, MD: Key Guideline Updates for Type 2 Diabetes

Carolyn J. Crandall, MD: Key Guideline Updates for Type 2 Diabetes

April 19th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

April 17th 2024
Podcast
Elena Christofides, MD | Credit: Endocrinology Associates

Insulin Glargine Biosimilar Demonstrates Bioequivalence to Originator for Type 2 Diabetes

April 13th 2024
Article
Manufacturing Costs for Diabetes Medicines Could Likely Be Lower | Image Credit: Harvard University

Manufacturing Costs for Diabetes Medicines Could Likely Be Lower, Study Finds

April 4th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.